Inventor

TRIEBEL FREDERIC

FR29 patents

⚠️ This page may combine multiple inventors who share the name “TRIEBEL FREDERIC”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

TRIEBEL FREDERIC

ROUSSY INST GUSTAVE

Soluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodies

Therapeutic composition containing antibodies to soluble polypeptide fractions of LAG-3 protein

Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment

Soluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodies

Mutated peptide compounds, derived from hsp70, useful in cancer immunotherapy

Peptide compounds derived from a shifted ORF of the iCE gene

IMMUTEP SAS

Combined preparations for the treatment of cancer

Combined preparations for the treatment of cancer or infection

Combined preparations for the treatment of cancer or infection

Combined preparations for the treatment of cancer or infection

Combined preparations for the treatment of cancer

ROUSSEL UCLAF

Nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses

Isolated Vβ TCR antibodies

Nucleotide sequence coding for variable regions of the α chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses

Nucleotide sequences for α chain variable regions in human lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses

INST NAT SANTE RECH MED

Proteins produced by human lymphocytes, DNA sequence encoding these proteins and their pharmaceutical and biological use

Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses

DNA encoding for a protein containing the extracellular domain of lymphocyte activation gene 3

APPLIED RESEARCH SYSTEMS

Mutants of the LAG-3 proteins and nucleotides encoding LAG-3 mutants

Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment

AVENTIS PHARMA SA

Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses

Nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses

IMMUTEP

Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response

Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response

NOVARTIS AG

Antibody molecules to LAG-3 and uses thereof

TRIEBEL FREDERIC

Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease

HOECHST MARION ROUSSEL INC

Nucleotide sequences coding for variable regions of the αchains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic muses

JOOSS KARIN

Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use

HERCEND THIERRY

Nucleotide sequence coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses